185 related articles for article (PubMed ID: 25652048)
1. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis.
Jones M; Hruby G; Solomon M; Rutherford N; Martin J
Ann Surg Oncol; 2015 Oct; 22(11):3574-81. PubMed ID: 25652048
[TBL] [Abstract][Full Text] [Related]
2. Role of positron emission tomography-computed tomography in the management of anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography in the staging and treatment of anal cancer.
Sveistrup J; Loft A; Berthelsen AK; Henriksen BM; Nielsen MB; Engelholm SA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):134-41. PubMed ID: 22000745
[TBL] [Abstract][Full Text] [Related]
4. PET/CT in anal cancer - is it worth doing?
Wells IT; Fox BM
Clin Radiol; 2012 Jun; 67(6):535-40. PubMed ID: 22208962
[TBL] [Abstract][Full Text] [Related]
5. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
[TBL] [Abstract][Full Text] [Related]
6. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up.
Saboo SS; Zukotynski K; Shinagare AB; Krajewski KM; Ramaiya N
Abdom Imaging; 2013 Aug; 38(4):728-35. PubMed ID: 23011550
[TBL] [Abstract][Full Text] [Related]
7. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
8. Role of
Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
[TBL] [Abstract][Full Text] [Related]
9. Assessing the impact of FDG-PET in the management of anal cancer.
Nguyen BT; Joon DL; Khoo V; Quong G; Chao M; Wada M; Joon ML; See A; Feigen M; Rykers K; Kai C; Zupan E; Scott A
Radiother Oncol; 2008 Jun; 87(3):376-82. PubMed ID: 18453023
[TBL] [Abstract][Full Text] [Related]
10. Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
Piperkova E; Raphael B; Altinyay M; Castellon I; Libes R; Sandella N; Abdel-Dayem H
J BUON; 2006; 11(4):523-7. PubMed ID: 17309188
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
12. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT imaging of anal canal squamous cell carcinoma.
Nguyen BD; Ram PC; Roarke MC
Clin Nucl Med; 2007 Mar; 32(3):234-6. PubMed ID: 17314608
[No Abstract] [Full Text] [Related]
15. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival.
Deantonio L; Milia ME; Cena T; Sacchetti G; Perotti C; Brambilla M; Turri L; Krengli M
Radiol Med; 2016 Jan; 121(1):54-9. PubMed ID: 26126968
[TBL] [Abstract][Full Text] [Related]
16. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
[TBL] [Abstract][Full Text] [Related]
17. To PET or not to PET? That is the question. Staging in anal cancer.
Bhuva NJ; Glynne-Jones R; Sonoda L; Wong WL; Harrison MK
Ann Oncol; 2012 Aug; 23(8):2078-2082. PubMed ID: 22294527
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
[TBL] [Abstract][Full Text] [Related]
19. Potential for truncating the scan length of restaging FDG-PET/CT after chemoradiotherapy in head and neck squamous cell carcinoma.
Huang YT; Ravi Kumar AS
Nucl Med Commun; 2012 May; 33(5):503-8. PubMed ID: 22262244
[TBL] [Abstract][Full Text] [Related]
20. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
